BIIB News 311.98 06/20/2014 04:30:26 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 311.98 $BIIB

Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human

Is This the Next Blockbuster MS Treatment?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jun 18, 4:30PM CDT
Biogen Idec   and its partner AbbVie reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the...

Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.

Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.

Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...

True North Therapeutics Announces $22 Million Series A Financing
Business Wire - Tue Jun 17, 6:00AM CDT
True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today that it has completed a $22 million Series A equity financing. Proceeds from the financing will be used to advance True North's lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015. The total Series A round encompasses initial funds from the spin-out of True North Therapeutics from iPierian, Inc., announced in September 2013. Investors in the Series A financing include Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures, and Baxter Ventures.

Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
PR Newswire - Tue Jun 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders and is the fourth collaboration between the two companies.

Our Drug Works! But There's a Catch ...
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 16, 5:21PM CDT
AFFiRiS' press release read like a monumental scientific discovery: Breakthrough in Alzheimer's disease: AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase II clinical study There's just one catch:...

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings -

Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec
Thomson Reuters ONE - Mon Jun 16, 1:01AM CDT
On Friday, 13 June, Swedish Orphan Biovitrum AB's (publ) (Sobi) received a data package from Biogen Idec regarding a preclinical Hemophilia A program based on Amunix's proprietary XTEN technology. Amunix and Biogen Idec signed a worldwide license agreement in April 2014. Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to obtain an option to add potential additional Factor VIII:Fc Constructs to the collaboration. Sobi has 120 days to review the preclinincal data, and to determine whether to elect to obtain such option under the collaboration. If Sobi elects to aquire its option, the company will be required to make a payment to Biogen Idec.

50-Day Moving Average Can Buffer A Strong Stock's Advance
at Investor's Business Daily - Fri Jun 13, 4:27PM CDT
It's frustrating to miss a heavy-volume breakout . The good thing is that the market likes to give second chances. If it's a truly a strong stock and the market is in a healthy uptrend, there will be plenty of other opportunities to buy it. The...

One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis
PR Newswire - Thu Jun 12, 11:00AM CDT
Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for Genzyme's Aubagio (69 percent) and Novartis's Gilenya (79 percent), despite the fact that Tecfidera is the third-to-market oral disease-modifying therapy (DMT) for MS. Driven by significant increases wave over wave, neurologist-reported Tecfidera patient share among DMT-treated relapsing-remitting MS (RR-MS) patients has grown to 13 percent and now exceeds that reported for Aubagio and Gilenya combined. Among high Tecfidera prescribers, Tecfidera is anticipated to become the RR-MS patient share leader as it will overtake Teva's Copaxone within the next six months.

3 Reasons to Watch Array Biopharma Inc.
Nathaniel Calloway, The Motley Fool - Motley Fool - Thu Jun 12, 9:56AM CDT
It is no secret that the risks associated with pharmaceutical development are considerable. The cost to develop a novel drug often exceeds $1 billion.  Many smaller biotechs support these high development costs by by offering licensing options to...

Watch for Biogen Idec to Potentially Rebound After Falling 1.50% Yesterday
Comtex SmarTrend(R) - Wed Jun 11, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.00 to a high of $314.99. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $312.61 on volume of 884,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful

FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.

RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
Business Wire - Wed Jun 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 321

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Embrace Pet Insurance Breaks Records in Volunteerism and Giving

Updated Category News Views 317

Embrace Pet Insurance Partners in Charity and Volunteerism Despite facing economic hurdles, charitable contributions across the nation showed remarkable resilience, highlighting the generosity of individuals and businesses alike. Recent reports reveal that charitable donations in the U.S. hit staggering heights, exceeding $557 billion in the last reporting year. Embrace...

Continue Reading
Sony's Innovative OLED Microdisplay Sets New Industry Standards

Updated Category News Views 210

Exploring Sony's Innovative OLED Technology Sony Semiconductor Solutions Corporation is about to change the landscape of augmented reality (AR) with the introduction of its groundbreaking ECX350F. This 0.44-type Full HD OLED Microdisplay is remarkable for its unique features, including the smallest pixel size in the industry and outstanding brightness. This innovation...

Continue Reading
Bascom Palmer Eye Institute Claims Top Spot in Medical Rankings

Updated Category News Views 269

Bascom Palmer Eye Institute's Unrivaled Recognition in 2025 For an impressive 24th consecutive year, Bascom Palmer Eye Institute has been honored as the premier ophthalmology hospital in the United States. This prestigious recognition, detailed in the 2025 U.S. News & World Report "Best Hospitals" rankings, underscores the institute's unwavering commitment to providing...

Continue Reading
Insights on Unusual Options Activity for Alphabet Inc.

Updated Category News Views 269

Unusual Options Activity Analysis for Alphabet Inc. Recent trends indicate that prominent financial players are adopting a bearish stance on Alphabet Inc. Our thorough analysis of options history for Alphabet (GOOGL) highlights 20 unusual trades, emphasizing a notable shift in market sentiment. Understanding Trader Sentiment Upon delving into the trade specifics, our...

Continue Reading
A Critical Juncture for uniQure Amidst Regulatory Challenges

Updated Category News Views 191

uniQure's Recent FDA Feedback The U.S. Food and Drug Administration (FDA) recently provided important insights to uniQure N.V. (NASDAQ: QURE) about its proposed gene therapy for Huntington’s disease. This feedback has led to a noticeable drop in the company’s stock price, reflecting heightened investor concern. Understanding AMT-130 AMT-130 is uniQure’s...

Continue Reading